Last reviewed · How we verify

NCT05250947

Study Evaluating the Safety and Feasibility of Platelet-rich Plasma to Treat Facetogenic Low Back Pain

Terminated Phase 1 Last updated 17 July 2024
What this trial tests

Phase 1 trial testing Angel® Concentrated Platelet Rich Plasma System in Lumbar Spondylosis in 4 participants. Terminated before completion.

Timeline
5 January 2023
Primary endpoint
20 May 2024
20 May 2024

Quick facts

Lead sponsorMatthew Pingree
PhasePhase 1
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment4
Start date5 January 2023
Primary completion20 May 2024
Estimated completion20 May 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Matthew Pingree

Who can join

Adults 22 to 70, any sex, with Lumbar Spondylosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is being done to assess the safety of using the Angel Concentrated Platelet Rich Plasma System to process Platelet Rich Plasma (PRP) to treat arthritis of the low back (lumbar spondylosis).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Lumbar Spondylosis

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05250947.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing